Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters

超低结垢抗感染抗血栓释放一氧化氮血管内导管

• 批准号: 10759671
• 负责人: Ronald J. Shebuski
• 金额: $ 119.31万
• 依托单位: NYTRICX INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10759671
• 关键词: Adhesions; Affect; Anti-Infective Agents; Antibiotic Resistance; Antibiotic Therapy; Antibiotics; Back; Bacteremia; Bacteria; Bacterial Adhesion; Binding; Bioreactors; Blood; Blood Platelets; Blood Vessels; Blood coagulation; Body part; Catheters; Cells; Cessation of life; Chronic; Clinical; Communities; Data; Development; Devices; Environment; Extracellular Matrix; Failure; Fibrinogen; Frequencies; Gases; Glycocalyx; Hemolysis; Heparin; Hospitals; Human; Immobilization; Immune; In Vitro; Infection; Infection prevention; Invaded; Kinetics; Life; Liquid substance; Mechanics; Medical; Medical Care Costs; Microbial Biofilms; Modeling; Nitric Oxide; Nitric Oxide Donors; Nosocomial Infections; Nutritional; Oryctolagus cuniculus; Patients; Phase; Platelet Activation; Polymers; Prevention; Proliferating; Property; Protein Structure Initiative; Proteins; Pseudomonas aeruginosa; Reporting; Resistance; Risk; Silicone Oils; Silicones; Solid; Staphylococcus aureus; Steam; Stream; Surface; Technology; Temperature; Tensile Strength; Therapeutic Embolization; Thromboembolism; Thrombosis; Thrombus; Time; Veins; Venous Thrombosis; antimicrobial; base; catheter related infection; chronic infection; combat; design; hemocompatibility; hydrophilicity; in vivo; innovation; microorganism; mortality; novel; pharmacologic; physical property; prevent; side effect; stability testing; thrombotic; venous thromboembolism

Abstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics the natural release by cells to prevent infection and thrombosis. The Nytricx technology is designed to combine anti-infective and anti-thrombotic properties of Nitric Oxide (NO) release at the internal and external catheter interfaces, which may be an extremely effective means to prolong catheter life, decrease chronic infection, and blood clotting (thrombosis) associated with intravascular catheters. The combination of a novel topcoats with NO gas release from the base silicone polymer is unique, especially considering that the NO donor itself stays embedded in the polymer with only the NO gas escaping to affect the external and internal catheter environments. The topcoat also affects biofilm formation which is also a chronic problem associated with catheter infections preventing effective antibiotic therapy. Nytricx NO-releasing technology represents a disruptive innovation that will result in saving patients’ lives and cutting medical costs, especially those related to hospital acquired blood steam infections and thrombosis, associated with intravascular catheters.

摘要 Nytricx正在开发一种新型的释放一氧化氮（NO）的血管内医疗导管， 与留置血管导管相关的感染和血栓形成。NO气体是一种天然的抗感染剂， 主要从血管和免疫细胞释放的抗血栓形成的人类产品。Nytricx NO释放 技术通过聚合物基质施加到导管表面，模拟细胞的自然释放，以防止感染 和血栓形成。Nytricx技术旨在将抗感染和抗血栓特性联合收割机结合起来， 一氧化氮（NO）释放在内部和外部导管接口，这可能是一个非常有效的 延长导管寿命、减少慢性感染和与之相关的凝血（血栓形成）的方法 血管内导管新型面漆与从基础有机硅聚合物释放的NO气体的组合 是独特的，特别是考虑到NO供体本身仅与NO气体一起保持嵌入聚合物中 逸出以影响导管的外部和内部环境。面漆也影响生物膜的形成 这也是与导管感染相关的慢性问题，妨碍了有效的抗生素治疗。尼特里克斯 NO释放技术代表了一种颠覆性的创新，它将挽救患者的生命， 医疗费用，特别是与医院获得性血液蒸汽感染和血栓形成有关的费用， 血管内导管。